Neurophet said on the 12th that it will introduce "Neurophet AQUA AD Plus" at the American Society of Neuroradiology. It is software that detects side effects that may occur during the process of administering treatments to Alzheimer's disease patients.
Alzheimer's disease is a degenerative neurological disorder caused by an excessive buildup of abnormal proteins in the brain. People lose memory and daily life becomes difficult, but it cannot be cured 100%. Symptoms are usually alleviated with medication.
Neurophet AQUA AD Plus analyzes brain MRI (magnetic resonance imaging) and positron emission tomography scans to monitor the use of Alzheimer's treatments. It determines whether a prescribed therapy is appropriate for a patient and whether side effects such as cerebral hemorrhage or cerebral edema occur during administration.
The conference will be held in Austin, the United States, from the 17th to the 20th. Ban Jun-gil, Neurophet's co-CEO, said, "We plan to expand global partnerships and supply products to local medical institutions."